



Final Appraisal Recommendation

Saxagliptin (Onglyza®)

Limited submission by:
Bristol Myers Squibb/AstraZeneca EEIG

Advice No: 2011 – December 2011

Recommendation of AWMSG

Saxagliptin (Onglyza®) is recommended as an option for use within NHS Wales as an add-on combination therapy for use in adult patients with type 2 diabetes mellitus with moderate or severe renal impairment to improve glycaemic control.

AWMSG is of the opinion that saxagliptin (Onglyza®) may be suitable for shared care within NHS Wales.

Additional notes:

This recommendation applies only to the use of Saxagliptin (Onglyza®) for the indication under consideration.

Saxagliptin (Onglyza®) for the above indication met the following criteria for eligibility for a limited submission:

- Minor licence extension
- Anticipated usage in NHS Wales is considered to be of minimal budgetary impact.

In reaching this recommendation AWMSG took account of the [AWMSG Secretariat Assessment Report](#), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, [clinical expert opinion](#), lay perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: